Abstract Number: 2322 • ACR Convergence 2025
Gender-related Differences in Peripheral and Axial Spondyloarthritis
Background/Purpose: This study sought to compare clinical characteristics between female and male patients with spondyloarthritis (SpA) in a Turkish population.Methods: This study included 489 peripheral…Abstract Number: 0571 • ACR Convergence 2025
Single-cell RNA Sequencing Highlights the Role of Innate Immunity in Identifying Candidates for Early Biologics Treatment in Axial Spondyloarthritis
Background/Purpose: Biologics have transformed the management of axial spondyloarthritis (axSpA). Currently, it is challenging to identify patients who would benefit from early biologics, resulting in…Abstract Number: 0104 • ACR Convergence 2025
Dissecting the Genetic and Functional Association of CARD9 with Axial Spondyloarthritis
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic immune-mediated inflammatory disease with strong genetic predisposition, driven by HLA-B27 and over 100 additional loci identified by genome-wide…Abstract Number: 2321 • ACR Convergence 2025
Uncovering Clinical Phenotypes of Sexual Dysfunction in Spondyloarthritis: A Multidimensional Analysis
Background/Purpose: Spondyloarthritis (SpA) impacts patient’s life, including functionality, QoL, emotional state, and sexual function. The current study was conducted to determine the frequency of sexual…Abstract Number: 0569 • ACR Convergence 2025
ASAS recommendations on reporting outcomes of core outcome set instruments in axial spondyloarthritis clinical trials
Background/Purpose: The recently updated Assessment of SpondyloArthritis international Society (ASAS) core outcome set (COS)includes an agreed minimum set of instruments that should be used in…Abstract Number: 0098 • ACR Convergence 2025
The Deubiquitinase TRABID is a Regulator of Osteogenesis and Inflammation in Spondyloarthritis:
Background/Purpose: Axial Spondyloarthritis (AxSpA) is characterized by both inflammation and new bone formation. Current therapeutic targets aim to control inflammation, however over 40% of patients…Abstract Number: 2690 • ACR Convergence 2025
Dietary interventions in Psoriatic Arthritis: A Randomized controlled clinical trial
Background/Purpose: The Dietary Interventions in Psoriatic Arthritis (DIPSA) study is a multicentre randomized controlled trial (RCT) designed to evaluate the efficacy of two personalized dietary…Abstract Number: 2312 • ACR Convergence 2025
Sociodemographic Characteristics and Healthcare Utilization in Patients with IBD-Associated Arthritis vs. IBD Alone: A Nationwide Inpatient Analysis
Background/Purpose: Inflammatory bowel disease (IBD)-associated arthritis (IBD-A) can affect 24-44% of IBD patients and may represent an enhanced inflammatory state. IBD-A patients often experience a…Abstract Number: 0568 • ACR Convergence 2025
Drug-Free Remission in Early Peripheral Spondyloarthritis: 10-year follow-up from the CRESPA-trial
Background/Purpose: Peripheral spondyloarthritis (pSpA) is a neglected clinical entity with few therapeutic or clinical management trials available to date. In the CRESPA-trial (1) very early…Abstract Number: 0099 • ACR Convergence 2025
Time course and impact of IL17A on hepatic inflammation and fibrosis in adjuvant induced arthritis
Background/Purpose: The management of spondyloarthritis. (SpA) includes controlling disease activity as well as comorbidities such as metabolic syndrome. Metabolic syndrome can be associated with metabolic…Abstract Number: 2687 • ACR Convergence 2025
Glucagon-like peptide-1 receptor agonists therapy is associated in improvement in psoriatic arthritis-related and metabolic outcomes: A retrospective analysis of two cohorts
Background/Purpose: Obesity is highly prevalent in psoriatic arthritis (PsA) and is associated with reduced therapeutic response, worse disease outcomes, and increased cardiometabolic risk. Glucagon-like peptide-1…Abstract Number: 2200 • ACR Convergence 2025
Obstetric and Neonatal Complications in Women living with Axial Spondyloarthritis: a population-based, matched cohort study
Background/Purpose: Women with axial spondyloarthritis (axSpA) are frequently diagnosed during their childbearing years. While studies have reported on pregnancy complications in this population, deriving generalizable…Abstract Number: 0553 • ACR Convergence 2025
Modified A-Tool: An online self-screening tool for axial spondyloarthritis for patients with chronic back pain
Background/Purpose: Lack of timely rheumatology referral of chronic back pain (CBP) patients with suspected axial spondyloarthritis (axSpA) is a major contributor to delayed diagnosis. We…Abstract Number: 0585 • ACR Convergence 2025
Fungal Infections, Including Candida, in Patients With Active Axial Spondyloarthritis Treated With Secukinumab: A Pooled Analysis of 10 Phase 3 Trials
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic disease characterized by inflammatory low back pain and is often accompanied by inflammation of the peripheral joints and…Abstract Number: 2676 • ACR Convergence 2025
Tofacitinib in Juvenile spondyloarthropathy: clinical efficacy, impact on biomarkers and comparison with Adalimumab
Background/Purpose: Tofacitinib is a JAK inhibitor that has been approved for treatment of polyarticular Juvenile idiopathic arthritis. However, data on its use in juvenile spondyloarthropathy…
- 1
- 2
- 3
- …
- 15
- Next Page »
